Latest Insider Transactions at Agilon Health, Inc. (AGL)
This section provides a real-time view of insider transactions for Agilon Health, Inc. (AGL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of agilon health, inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of agilon health, inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
5,396
-33.21%
|
$102,524
$19.88 P/Share
|
|
Jun 22
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+24.93%
|
$21,584
$4.49 P/Share
|
|
Jun 10
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
5,396
-33.21%
|
$102,524
$19.33 P/Share
|
|
Jun 10
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+24.93%
|
$21,584
$4.49 P/Share
|
|
Jun 09
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
5,396
-33.21%
|
$107,920
$20.9 P/Share
|
|
Jun 09
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+24.93%
|
$21,584
$4.49 P/Share
|
|
May 31
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
5,396
-33.21%
|
$102,524
$19.77 P/Share
|
|
May 31
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+24.93%
|
$21,584
$4.49 P/Share
|
|
May 27
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
5,396
-33.21%
|
$102,524
$19.58 P/Share
|
|
May 27
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+24.93%
|
$21,584
$4.49 P/Share
|
|
May 25
2022
|
Michael L Smith Director |
SELL
Open market or private sale
|
Indirect |
145,874
-97.25%
|
$2,771,606
$19.53 P/Share
|
|
May 11
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
5,396
-33.21%
|
$80,940
$15.95 P/Share
|
|
May 11
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+24.93%
|
$21,584
$4.49 P/Share
|
|
May 10
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
5,396
-17.03%
|
$86,336
$16.84 P/Share
|
|
May 10
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+24.93%
|
$21,584
$4.49 P/Share
|
|
Apr 28
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
5,396
-33.21%
|
$97,128
$18.3 P/Share
|
|
Apr 28
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+24.93%
|
$21,584
$4.49 P/Share
|
|
Apr 27
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
5,396
-33.21%
|
$97,128
$18.68 P/Share
|
|
Apr 27
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+24.93%
|
$21,584
$4.49 P/Share
|
|
Apr 22
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
SELL
Open market or private sale
|
Direct |
26,789
-8.78%
|
$535,780
$20.0 P/Share
|
|
Apr 22
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,789
+8.07%
|
$26,789
$1.0 P/Share
|
|
Apr 21
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
SELL
Open market or private sale
|
Direct |
79,568
-11.45%
|
$1,591,360
$20.89 P/Share
|
|
Apr 21
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
79,568
+18.19%
|
$79,568
$1.0 P/Share
|
|
Apr 20
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
SELL
Open market or private sale
|
Direct |
106,357
-27.66%
|
$2,339,854
$22.34 P/Share
|
|
Apr 20
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
106,357
+21.66%
|
$106,357
$1.0 P/Share
|
|
Apr 19
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
SELL
Open market or private sale
|
Direct |
106,357
-27.66%
|
$2,339,854
$22.74 P/Share
|
|
Apr 19
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
106,357
+21.66%
|
$106,357
$1.0 P/Share
|
|
Apr 19
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
6,296
-36.71%
|
$138,512
$22.14 P/Share
|
|
Apr 19
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,296
+26.85%
|
$25,184
$4.49 P/Share
|
|
Apr 18
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
SELL
Open market or private sale
|
Direct |
6,477
-37.37%
|
$142,494
$22.64 P/Share
|
|
Apr 18
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,477
+27.21%
|
$25,908
$4.49 P/Share
|
|
Apr 14
2022
|
Timothy Bensley Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,546
+32.22%
|
-
|
|
Apr 14
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,255
+5.52%
|
-
|
|
Apr 14
2022
|
Michelle A Gourdine Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,936
+26.85%
|
-
|
|
Apr 14
2022
|
Benjamin Kornitzer Chief Med. & Quality Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,419
+33.3%
|
-
|
|
Apr 14
2022
|
Sharad Mansukani Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,936
+0.56%
|
-
|
|
Apr 14
2022
|
Karen Mc Loughlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,936
+39.95%
|
-
|
|
Apr 14
2022
|
Clay Richards Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,936
+16.31%
|
-
|
|
Apr 14
2022
|
Steven Sell CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
48,765
+50.0%
|
-
|
|
Apr 14
2022
|
Benjamin Shaker Chief Markets Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,546
+14.89%
|
-
|
|
Apr 14
2022
|
Michael L Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,936
+4.18%
|
-
|
|
Apr 14
2022
|
Glenn Sobotka Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,439
+29.97%
|
-
|
|
Apr 14
2022
|
Girish Venkatachaliah Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,837
+39.98%
|
-
|
|
Apr 14
2022
|
Ronald A Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,936
+0.28%
|
-
|
|
Apr 14
2022
|
John William Wulf Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,936
+5.32%
|
-
|
|
Apr 07
2022
|
Benjamin Shaker Chief Markets Officer |
SELL
Open market or private sale
|
Direct |
2,706
-4.06%
|
$67,650
$25.01 P/Share
|
|
Mar 16
2022
|
Benjamin Shaker Chief Markets Officer |
SELL
Open market or private sale
|
Direct |
37,155
-35.8%
|
$743,100
$20.2 P/Share
|
|
Mar 16
2022
|
Benjamin Shaker Chief Markets Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,155
+26.36%
|
$111,465
$3.0 P/Share
|
|
Mar 16
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
SELL
Open market or private sale
|
Direct |
197,291
-42.96%
|
$3,945,820
$20.41 P/Share
|
|
Mar 16
2022
|
Veeral Desai Chief Strategy & Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
197,291
+30.05%
|
$197,291
$1.0 P/Share
|